Organon & Co. specializes in the development, manufacture and marketing of pharmaceutical products for women’s health, biosimilar medicines and drugs for the treatment of cardiovascular, respiratory and dermatological diseases. Net sales break down by family of products as follows: – medicines for women’s health (25.6%): contraceptives (Nexplanon, NuvaRing, CerazetteTM, Marvelon and Mercilon brands), medicines for women’s reproductive health (Follistim, ElonvaTM and Ganirelix Acetate Injection) and medicines for the treatment of post-partum hemorrhage; – drugs for the treatment of cardiovascular diseases (25.6%); – drugs for the treatment of respiratory diseases (16%); – drugs for the treatment of pain, bone pathologies and skin diseases (13.2%); – biosimilar medicines (6.7%): for the treatment of autoimmune diseases (Hadlima, Brenzys and Renflexis) and oncological diseases (Aybintio and Ontruzant); – other (12.9%). At the end of 2021, the Group had 6 production sites located in Brazil, the United Kingdom, Belgium, the Netherlands, Indonesia and Mexico. Net sales are distributed geographically as follows: the United States (21.9%), Europe and Canada (27.6%), China (14.8%), Asia/Pacific (18.6%), Latin America/Middle East/Russia/Africa (13.4%) and other (3.7%).
Source: marketscreener.com
